New CEO will also serve on biotechnology research company’s Board of Directors
SOUTH RIDING, VA. – July 28, 2022 – Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of George Cardoza as Chief Executive Officer (CEO) and as member of the Board of Directors at AccuraGen, a biotechnology research company that has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment.
Cardoza joins AccuraGen following a 12-year tenure at NeoGenomics Laboratories where he served as Chief Financial Officer (CFO) from 2009-2018; President, Pharma Services Division from 2018-2021; and as President and Chief Operating Officer (COO), Lab Operations from 2021-2022. Earlier in his career Cardoza served as CFO at Protocol Integrated Direct Marketing; CFO of Protocol Marketing; and Controller, Central Region at Quest Diagnostics.
“George Cardoza is a highly accomplished financial and operations leader with a solid track record of success in the life sciences industry,” said Slone Partners President Tara Kochis. “He is smart, passionate, and visionary with impeccable credentials, and will be a terrific addition to the AccuraGen leadership team.”
“We are thrilled to have George join AccuraGen as CEO and lead us into the next phase for the company. We also are grateful to Kang for his contribution as CEO and look forward to continuing to work closely with him in China and at the Board,” said Dan Zabrowski, Board Member of AccuraGen and Venture Partner, Decheng Capital.
“I’m honored and excited to be the new CEO of AccuraGen,” said Cardoza. “I’m looking forward to working with the teams in both United States and China. I’ve been extremely impressed by the teams and the technology that they have developed as the Company is a hidden gem. AccuraGen’s platform can be used by laboratories around the world to improve patient care.”
Cardoza earned his Bachelor’s Degree in Finance and Accounting from Syracuse University and his M.B.A. in Management from Michigan State University Eli Broad College of Business.
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit www.slonepartners.com or call 888.784.3422.
AccuraGen aims to revolutionize cancer management through technology innovation in molecular testing. AccuraGen focuses on the analysis of highly fragmented circulating nucleic acid in blood and has developed proprietary technologies enabling superior performance in the analysis of genomic, epigenetic, and RNA changes. AccuraGen is headquartered in San Jose, California, USA with CAP-accredited facility in Shanghai, China. To learn more about the company, visit https://www.accuragen.com/.